The most ubiquitous BiTE in clinical practice for hematologic malignancies is blinatumomab, a bispecific monoclonal antibody construct which simultaneously binds CD3-positive cytotoxic T-cells and CD19-positive B-cells to activate T-cell recognition and killing of CD19 positive blasts [12,13]. Here, CD19 is linked to hematologic disorder.